tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
ProQR Advances AX-0810 into Clinical Trials for Cholestatic Diseases
PremiumCompany AnnouncementsProQR Advances AX-0810 into Clinical Trials for Cholestatic Diseases
2M ago
PRQR Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
PRQR Upcoming Earnings Report: What to Expect?
2M ago
ProQR Receives CTA Authorization for AX-0810 and Plans Investor Event
Premium
Company Announcements
ProQR Receives CTA Authorization for AX-0810 and Plans Investor Event
2M ago
ProQR’s Strategic Advancements and Clinical Prospects Drive Buy Rating
PremiumRatingsProQR’s Strategic Advancements and Clinical Prospects Drive Buy Rating
5M ago
ProQR Reports Q2 2025 Financial Results Amid Rising R&D Costs
Premium
Company Announcements
ProQR Reports Q2 2025 Financial Results Amid Rising R&D Costs
5M ago
ProQR Therapeutics reports Q2 EPS (EUR 0.21) vs. (EUR 0.13) last year
Premium
The Fly
ProQR Therapeutics reports Q2 EPS (EUR 0.21) vs. (EUR 0.13) last year
5M ago
ProQR Therapeutics Reports Q1 2025 Financial Results
PremiumCompany AnnouncementsProQR Therapeutics Reports Q1 2025 Financial Results
7M ago
ProQR Therapeutics price target lowered to $9 from $15 at Oppenheimer
Premium
The Fly
ProQR Therapeutics price target lowered to $9 from $15 at Oppenheimer
8M ago
ProQR’s Innovative RNA Editing Platform and Promising AX-0810 Program Drive Buy Rating
Premium
Ratings
ProQR’s Innovative RNA Editing Platform and Promising AX-0810 Program Drive Buy Rating
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100